Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this animal study, finasteride treatment altered testosterone metabolism in rat corpus cavernosum, linked to mechanisms of erectile dysfunction, but these changes were reversed after stopping the drug, suggesting post-treatment sexual side effects may relate more to central control dysfunction than peripheral issues.

This editorial comment references research on finasteride's effects on urinary retention and surgical needs in benign prostatic hyperplasia but reports no new findings.

In this study, men with benign prostatic hyperplasia who took finasteride for four years experienced reduced urinary symptoms, fewer surgeries, less acute urinary retention, increased urinary flow rates, and decreased prostate volume.

This study suggests that the negative impact of high-dose Finasteride on male reproductive function may be mitigated by concurrent administration with TU.

This review summarized existing research on finasteride and erectile dysfunction, finding a correlation between finasteride use for benign prostatic hyperplasia and ED, but not strongly for male androgenetic alopecia.

This study found that Italian dermatologists commonly prescribe 1 mg/day finasteride for androgenetic alopecia despite reported sexual side effects, due to its perceived long-term efficacy.

Finasteride reduces prostate size and symptoms with few side effects.

This review discusses the adverse events associated with 5-alpha reductase inhibitors, finding them generally well-tolerated but noting potential risks like sexual side effects and psychological effects in men, and sparse data on use in women.

This study determined that men taking finasteride 1 mg/day exhibited significantly reduced sperm production and morphology compared to controls, although there were no notable changes in hormonal, sexual, or psychological function.

This review discusses the role of finasteride preoperatively in reducing bleeding and complications during TURP and reports no new clinical results; the authors emphasize its potential benefits based on existing studies.

This article discusses Truman Plus Male Enhancement, a testosterone booster, emphasizing its potential benefits for sexual health and energy, but does not report any new clinical results.

Off-label drug use can be risky and requires careful consideration to ensure patient safety.

This analysis concluded that preoperative finasteride significantly reduced blood loss during transurethral resection of the prostate by potentially decreasing the expression of VEGF and microvessel density.

Finasteride may cause sexual dysfunction by reducing epinephrine levels.

This study found that finasteride significantly reduced serum dihydrotestosterone levels, confirming its efficacy as a 5a-reductase inhibitor, while Permixon showed no effect in healthy male volunteers.

The conclusion is that future trials should report specific details about the PRP composition to better understand its effects on urologic conditions.

This study observed that men receiving dutasteride for benign prostatic hyperplasia did not show significant differences in neuropsychological assessments compared to a control group not on dutasteride.

Created microspheres show potential for safe and effective use in prostate artery embolization.

This hypothesis paper suggests that sexual and cognitive dysfunctions reported by some men after using finasteride and dutasteride may stem from vascular and tissue changes in penile tissue triggering broader inflammatory effects.

This study concluded that dutasteride modestly reduces nocturia in men but does not improve sleep quality.

This study found that prescribing finasteride for two weeks before TURP surgery reduces intraoperative and postoperative blood loss, the rate of blood transfusion, and irrigation fluid usage in patients with BPH.

This study suggests that Low-level Laser Therapy may improve pain and quality of life in women with Chronic Pelvic Pain Syndrome, though larger studies are needed to confirm these findings.

This study found no significant benefit of platelet-rich plasma injections over placebo in improving erectile function in patients with mild to moderate erectile dysfunction.

Combination therapy for 9+ months maintains symptom improvements after stopping alpha-blockers or finasteride.

This study identified specific genes and pathways in human Leydig cells that may contribute to Post-finasteride Syndrome, potentially informing future treatments to reverse persistent side effects.